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Abtract
Background: Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver diseases, ranging from pure 
steatosis to nonalcoholic steatohepatitis (NASH), and eventually to liver cirrhosis with its complications. Identifying 
advanced fibrosis in patients is crucial to evaluating prognosis and possible therapeutic intervention. A novel, simple, 
and highly accurate scoring system called BARD, which identifies patients with NAFLD and without significant fibrosis, 
has been recently introduced and validated in North America..The aim of this study is to validate the BARD scoring 
system in a Polish cohort with NAFLD.
Methods: A group of 104 Caucasians with biopsy-proven NAFLD were included in this study. Fibrosis in liver biopsies 
was evaluated according to the Histological Scoring System for Nonalcoholic Fatty Liver Disease. The BARD scoring 
system was assessed according to Harrison et al.: BMI ≥ 28 = 1 point, AST/ALT ratio (AAR) ≥ 0.8 = 2 points, type 2 
diabetes mellitus = 1point.
Results: Age over 50 and AAR over 0.8 showed, respectively, a moderate and strong association with advanced fibrosis. 
A BARD score of 2-4 points was associated with F3 or F4 stages of fibrosis with an odds ratio of 17.333 (95% Cl; 3,639 - 
82.558) and negative predictive value of 97%.
Conclusion: Our results demonstrate that the BARD scoring system has value in the non-invasive diagnosis of 
advanced fibrosis in NAFLD patients. The vast majority of patients with NAFLD would avoid liver biopsy if BARD was 
broadly introduced into the clinic.
Background
Nonalcoholic fatty liver disease (NAFLD) includes a wide
spectrum of liver pathologies, ranging from pure steatosis
(usually a benign and non-progressive condition) to non-
alcoholic steatohepatitis (NASH), which may progress to
liver cirrhosis with complications such as portal hyper-
tension and hepatocellular carcinoma [1]. NAFLD is now
considered an early expression of the metabolic syn-
drome [2]. This liver disease is also an independent risk
factor for type 2 diabetes mellitus (DMt2) and atheroscle-
rotic cardiovascular events [3].
NAFLD seems to be a growing problem due to the epi-
demic of obesity. Data from the United States suggests
that up to 30% and 3-5% of the general population have
NAFLD and NASH, respectively. The prevalence of
NASH may attain 25-75% among morbidly obese patients
[4]. The natural history of NAFLD shows that histopatho-
logical progression occurs in 32-37% of patients over 3-6
years and up to 12% of patients may progress to cirrhosis
over 8-10 years [4].
Liver fibrosis, once considered irreversible, is now rec-
ognized as a dynamic process with significant likelihood
of remission. Therefore, identifying patients with
advanced fibrosis is crucial to the accurate evaluation of
prognosis, need of surveillance, and therapeutic interven-
tion. The liver biopsy is still the best available standard in
the assessment of liver fibrosis. However, liver biopsy has
limitations due to invasiveness, small tissue samples, and
inter- and intra-observer error. Moreover, liver biopsy is
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not appropriate to regularly monitor fibrosis progression
or response to treatment [4]. Recent evidence indicates
that certain demographic and clinical data show relation-
ships with advanced fibrosis in NAFLD patients [5]. On
this basis, Angulo et al. [5] proposed a screening algo-
rithm (NAFLD Fibrosis Score) composed of easily obtain-
able independent indicators of advanced fibrosis, such as
age, serum glucose, body mass index (BMI), platelet
count, serum albumin, and aspartate aminotransferase/
alanine transaminase (AST/ALT) ratio. A scoring system
with these 6 variables has an area under the receiver
operating characteristic (AUROC) curve of 0.88, with
negative predictive value (NPV) of 93% and positive pre-
dictive value (PPV) of 90%. NAFLD Fibrosis Score distin-
guishes patients lacking fibrosis and patients with
significant fibrosis, but remains approximately 25% diag-
nostically uncertain [5]. Other scoring systems, such as
the Original European Liver Fibrosis Panel (OELF) or
Enhanced Liver Fibrosis (ELF), detect advanced fibrosis.
However, their use of parameters not easily available in
clinics poses an obvious disadvantage [6]. Negative pre-
diction values of advanced fibrosis for ELF and OELF
were 82% and 89%, respectively. Very recently, Harrison
et al.[4] proposed the BARD score, which takes into
account body-mass index (BMI), AST/ALT ratio (AAR),
and presence of type 2 diabetes mellitus (DMt2). These
three simple variables were combined in a weighted sum
to form a score for predicting advanced fibrosis. A score
of 2-4 was associated with an odds ratio for advanced
fibrosis of 17 (95% CI: 9.2 to 31.9) and a negative predic-
tive value of 96% [4].
The aim of this study was to validate the BARD scoring
system in ethnically homogenous Polish patients with
histopathologically diagnosed NAFLD. This study was
implanted because the Polish population is formed by a
scare number of Afro-Americans and the incidence of
obesity is relatively low in confront to the USA figures.
Methods
The BARD system was retrospectively tested on a cohort
of 104 Caucasian patients referred to two Polish liver cen-
ters due to elevated liver enzymes and/or hyperintense
echo on abdominal ultrasound. Study was approved by
the Ethic Committee of Pomeranian Medical University
in Szczecin, Poland. Only the patients with biopsy-proven
fatty liver (more than 5% of steatotic hepatocytes) who
also had a negative history of alcohol intake (i.e., patients
consuming less than 20 g/day) were included in this
study. All patients tested negative for viral hepatitis B and
C (HBs-Antigen and HCV-Antibodies) Patients aged 40
years or less had their ceruloplasmin checked and found
normal. Demographic and routine laboratory data were
extracted from the database. Liver biopsies were assessed
according to the Histological Scoring System for Nonal-
coholic Fatty Liver Disease and advanced fibrosis was
defined as bridging fibrosis and cirrhosis (F3 and F4).
BARD score was calculated by designating 0-2 points to
following parameters: BMI ≥ 28 kg/m2 = 1 point, BMI <
28 kg/m2 = 0 point; AST/ALT ratio ≥ 0.8 = 2 points, AST/
ALT ratio < 0,8 = 0 points; freshly recognized or preexist-
ing DMt2 = 1 point. According to original methods, a
total of 2-4 points indicates significant fibrosis.
S t a t i s t i c a l  a n a l y s e s  w e r e  p e r f o r m e d  w i t h  χ 2  and
ANOVA tests using SPSS (Statistical Package for the
Social Sciences) version 15.0.1 (evaluation version) statis-
tical software.
Results
The analyzed cohort consisted of 36 (34.6%) females and
68 (65,4%) males. The median age of patients was 50
years (range in females 30-70 years, in males 23-64 years).
BMI in females ranged from 20.0 kg/m2 to 39.3 kg/m2 and
in males from 21.9 kg/m2 to 37.7 kg/m2. More than half of
patients were obese (BMI > 30 kg/m2) and 38.1% were
overweight (BMI 25-30 kg/m2). Tests revealed hypercho-
lesterolemia (>5.18 mmol/L) in 68.9% of patients, hyper-
triglyceridaemia (>2.03 mmol/L) in 31.2%, DMt2 in
17.8%, and arterial hypertension in 29.7% of individuals.
Patients' selected demographic and clinical data are pre-
sented in Table 1.
Advanced fibrosis was significantly more common in
older patients with higher AST/ALT ratios. BMI, gender,
and serum AST activity were not significant risk factors
for advanced fibrosis in this study. Serum ALT level was
lower in patients with F3 and F4 fibrosis stages. Diabetes
was twice as frequent in patients with advanced fibrosis,
but this difference did not reach clinical significance (p =
109). In the population of patients with severe fibrosis
(F3-F4) the mean platelet count was significantly lower
and mean serum levels of glucose and insulin, as well as
HOMA index, were significantly higher in comparison to
patients with no or mild fibrosis (F0-F2). No differences
were found between serum albumin and glycated hemo-
globin levels. The comparative statistics between both
groups of patients are summarized in Table 2 and data on
relationships between clinical parameters and advanced
fibrosis are shown in Table 3. Age ≥ 50 years and AAR ≥
0 . 8  w e r e  a s s o c i a t e d  w i t h  i n c r e a s e d  r i s k  o f  s e v e r e  l i v e r
fibrosis. Age ≥ 50 years moderately increased the risk of
advanced fibrosis by a factor of 3.455 (95% CI 1.021-
11.694). This wide confidence interval depends on the
small number of cases and the BARD components seem
to be more valuable as less dependent on number of par-
ticipants. AAR ≥ 0.8 increased advanced fibrosis risk by a
factor of 27.
Analysis of the AUROC for BARD was 0.821 (p < 0.001)
(see Fig. 1) with an OR of 17.3 (95% CI: 3.64-82.56). TheRaszeja-Wyszomirska et al. BMC Gastroenterology 2010, 10:67
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positive and negative predictive values for detecting
fibrosis stages F3 or F4 were 35.1% and 97%, respectively.
BARD score was characterized by a sensitivity of 86.7%
and a specificity 72.7%, when 2 points were set as cut-off
value.
Discussion
The natural history of NAFLD remains poorly under-
stood and the search for noninvasive methods with which
to identify patients with advanced fibrosis and cirrhosis
remains a key issue. The ideal test for fibrosis in NAFLD
has to be simple, amenable to repeated monitoring, inex-
pensive, reliable, and able to detect the specific degree of
fibrosis. Most studies have focused on the identification
of severe fibrosis (F3, F4) as these patients have increased
risk of hemodynamic or metabolic decompensation and
development of liver cancer [7]. Despite the large number
of studies (at least 29 since 1999), no simple scoring sys-
tem that is able to discriminate between severe and no/
mild fibrosis in NAFLD patients has been widely popular-
ized.
The present study provides a detailed, descriptive clini-
cal and histopathological analysis of 104 patients with
biopsy-proven NAFLD. In this cohort we validated the
BARD scoring system, which has recently been devel-
oped as a composite score based on the weighted sum of
three variables: BMI ≥ 28, AAR ≥ 0.8 and presence of
DMt2. These variables were selected as the most useful
clinical markers of advanced fibrosis by univariate analy-
sis and forced entry logistic regression performed in a
large cohort of 827 patients with NAFLD [4].
The patients analyzed in the present study differ from
the patients analyzed in the original study with respect to
several important characteristics. First, our analysis is
specific to a significantly smaller but ethnically homoge-
nous group of Caucasian patients, diagnosed in two ter-
tiary hepatological centers. Harrison's study [4]
comprised an ethnically heterogeneous population in
which 32% of patients were non-Caucasian. The ethnic
structure of a cohort study is important for any scoring
system, as susceptibility to liver steatosis and fibrosis may
be related to different genetic and environmental factors.
In accordance, Fujii et al.[8] reported significantly worse
applicability of BARD in Japanese patients with NAFLD.
It is also worthwhile to mention that in Shah et al. study
[9] with 541 adults with NAFLD, not racially homoge-
neous, AUROC for BARD was much lower (only 0.70).
Second, unlike Harrison's study, males dominated in
our cohort (66% vs. 49%). Although NASH was initially
described as a disease affecting mostly women [10], fur-
ther studies have not confirmed gender differences in
variable NAFLD populations [11].
Table 1: Clinical characteristics of patients with NAFLD
Variable Normal values Median Mean ± SD Ranges
Age (years) 50 48.0 ± 12.0 26-70
BMI (19-25 kg/m2) 29.8 29.6 ± 3.84 21.2-39.3
AST(n = 115) (<38 IU/L) 44.0 51.5 ± 34.9 13-275
ALT(n = 117) (<41 IU/L) 71.0 80.8 ± 55.3 9-290
AST/ALT ratio 0.66 0.79 ± 0.58 0.34-5.23
Glucose (n = 118) (3.89-5.83 mmol/L) 5.44 5.69 ± 1.29 3.44-11.8
Insulin (n = 89) (41.7-187.5 pmol/L) 95.8 152.7 ± 191 13.9-972.3
PLT(n = 118) (150-400 × 109/L) 223 223 ± 62.5 93-376
Albumin (n = 107) (34-48 g/L) 43.0 43.0 ± 4.0 36.0-58.8
HBA1c (n = 37) (4.8-5.9%) 5.8 6.2 ± 1.2 4.99-9.6
HOMA (n = 89) (<1.8) 3.4 5.9 ± 7.8 0.44-38.91Raszeja-Wyszomirska et al. BMC Gastroenterology 2010, 10:67
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Third, Polish patients are less obese than the patients
participating in the American study. The median BMI in
our study was less than 30 kg/m2 compared to 33 kg/m2 in
Harrison's work, and no patient presented with morbid
obesity (16% of patients in Harrison's group were classi-
fied as morbidly obese). Moreover, in our cohort 10% of
individuals had normal BMI, compared to 3% in Harri-
son's group. Regarding body weight, Polish patients had
intermediate characteristics between American and
Asian populations with NAFLD [4,8]. It is likely that dif-
ferences in BMI set point, a component of BARD, should
be applied to different populations. Although increased
BMI is usually found in patients with metabolic syn-
drome, the central distribution of fat seems to be more
important than BMI in the pathogenesis of NAFLD.
Finally, only 18% of Polish patients suffered from DMt2,
compared to 35% in Harrison's study [4]. The low number
of patients with diagnosed diabetes could also influence
our results, as many studies have found that DMt2 is a
major predictor of hepatic fibrosis [12].
Marchesini et al.[13] showed that in NAFLD patients a
normal or moderately increased body weight and normo-
Table 2: Comparison of clinical data between patients with no/mild and advanced fibrosis
Variable normal values Fibrosis 0-2 (n = 88) Fibrosis 3-4 (n = 15) p
Age (years) 45.0 ± 12.0 53.0 ± 9.0 P = 0.028
BMI (19-25 kg/m2) 29.5 ± 3.61 30.79 ± 4.90 P = 0.221
AST (<38 IU/L) 52.73 ± 33.36 69.20 ± 45.18 P = 0.097
ALT (<41IU/L) 91.60 ± 56.94 61.53 ± 37.25 P = 0.052
AST/ALT ratio 0.69 ± 0.56 1.32 ± 0.57 P < 0.001
Glucose (3.89-5.83 mmol/L) 5.5 ± 1.08 6.99 ± 1.98 P = 0.011
Insulin (41.7-187.5 pmol/L) 132 ± 184 249.3 ± 148.6 P = 0.037
PLT (150-400x109/L) 226.6 ± 61,9 192.3 ± 63.9 P = 0.051
Albumin (34-48 g/L) 43 ± 4.0 43 ± 4.0 P = 0.842
HBA1c (4.8-5.9%) 5.8 ± 1.0 7.5 ± 1.8 P = 0.108
HOMA (<1.8) 4.6 ± 6.2 12.2 ± 9.8 P = 0.030
Table 3: Risk assessment of clinical parameters for advanced fibrosis
Variable Fibrosis 0-2 (n = 88) Fibrosis 3-4 (n = 15) p OR 95% CI
Age ≥ 50 years 39 (44.3%) 11 (73.3%) 0.038 3.455 1.021-11.694
BMI ≥ 28 58 (65.9%) 10 (66.7%) 0.954 1.034 0.324-3.302
DMt2 14 (15.9%) 5 (33.3%) 0.109 2.643 0.783-8.916
HOMA (<1.8) 32(46.4%) 7(70%) 0.193 2.698 0.644-11.306
AST/ALT ≥ 0,8 17 (19.3%) 13 (86.7%) p < 
0.001
27.147 5.592-131.974Raszeja-Wyszomirska et al. BMC Gastroenterology 2010, 10:67
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glycemia may be associated with clinical and laboratory
data similar to those found in obese diabetic patients. The
r i s k  o f  a d v a n c e d  f i b r o s i s  i n  p a t i e n t s  w i t h  a b n o r m a l
HOMA (>1.8) was increased by a factor of 2.7 in our
study. This finding strongly suggests that insulin resis-
tance is a key factor triggering fibrosis. Underestimation
of DMt2 in our study is an argument for advising oral glu-
cose tolerance tests as a routine strategy in the assess-
ment of patients with NAFLD [14].
Despite major differences in the two populations, we
obtained very similar results to Harrison's work, indicat-
ing that BARD has high predictive value in the diagnosis
of advanced fibrosis. In Polish NAFLD patients a BARD
score of 2-4 was associated with an OR of 17.33 of
advanced fibrosis. The composite score for sensitivity and
specifity, as determined by AUROC in our study, was
equivalent to the originally described score (0.82 vs. 0.81,
respectively). Similarly, in our study negative prediction
of advanced fibrosis (NPV 97%) was much better than its
positive prediction (PPV 35.1%). In other words, BARD's
results yielded a very low number of false negative and
high number of false positive diagnoses of significant
fibrosis. Negative prediction of fibrosis in NAFLD
patients was better than using ELF or OELF scoring sys-
tems (82% and 88%, respectively), based on non-routine
la bora t o ry da ta [6] . In our  s t udy ,  BARD w oul d pe rm i t
avoidance of liver biopsies in 100 of 104 patients who did
not require this procedure.
Our results, similar to originally described, were
obtained in smaller population of patients with NAFLD.
However the results of Shah et al.[9] were different
despite the number of participants: 541 vs 827 in Harri-
son et al. work [4]. It is of importance to note down that
the AUROC for the NAFLD Fibrosis Score was also lower
in Shah's [9] study than in original Angulo et al. [5] paper
and the FIB4 with the AUROC of 0.8 was superior of the
other noninvasive panels tested this work. Studies men-
tioned above demonstrated utility of noninvasive panels
to stage liver disease as well as their limitation. The first
limitation of all these studies is considerable sampling
variability in fibrosis staging in liver biopsies and the sec-
ond is the analyzed cohort with a broad distribution of
fibrosis stage and low number of patients with advanced
fibrosis. It is also important to notice that neo-fibrogene-
sis is present in fatty liver, as showed by Tarantino et. al
[15]. The results of our study showed that the BARD
scoring system is useful despite moderate number of par-
ticipants with severe fibrosis. It seems that improving
BARD's diagnostic sensitivity would necessitate incorpo-
ration of the markers of subclinical portal hypertension
(e.g., platelet count) and hepatic synthetic capacity (e.g.,
albumin). This conclusion is justified by the satisfactory
positive prediction of advanced fibrosis by the NAFLD
fibrosis scoring system proposed by Angulo et al. [5]. This
is also the idea of searching the perfect test to replace
liver biopsy.
In populations of patients with more advanced fibrosis,
univariate analysis revealed that age ≥50 and AAR ≥ 0.8
were risk factors of severe liver fibrosis. The mean AAR
in patients with advanced fibrosis was 1.32, definitely the
strongest predictor of advanced fibrosis (OR: 27.15).
Interestingly, high AAR resulted from both the lower lev-
els of ALT and higher levels of AST in the subgroup of
patients with significant fibrosis. There are several
hypotheses explaining an influence of progressive fibrosis
on aminotransferase activity, but none have been fully
validated.
An ideal noninvasive test for assessment hepatic fibro-
sis would be one that is sensitive, specific, free of addi-
tional cost to the patient, and applicable across all chronic
liver diseases. The BARD scoring system is one of the
attempt to create such a score although an ideal test does
not exist till now.
Conclusion
BARD reliably identifies patients without significant
fibrosis, providing the opportunity to avoid liver biopsy in
a large proportion of patients with NAFLD. This simple
scoring system shows utility and applicability to Cauca-
sian populations with NAFLD.
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Figure 1 Simple steatosis plus non-alcoholic steatohepatitis 
(NASH) with fibrosis stages 0-2 vs. NASH with fibrosis stages 3-4.
1 - Specificity
1,0 0,8 0,6 0,4 0,2 0,0
S
e
n
s
i
t
i
v
i
t
y
1,0
0,8
0,6
0,4
0,2
0,0
Diagonal segments are produced by ties.Raszeja-Wyszomirska et al. BMC Gastroenterology 2010, 10:67
http://www.biomedcentral.com/1471-230X/10/67
Page 6 of 6
Acknowledgements
This paper was supported by a grant from State Committee for Scientific 
Research, 2006-2009, No N 402 099 31/3037.
Author Details
1Liver Unit, Pomeranian Medical University, Szczecin, Poland, 2West-
Pomeranian University of Technology, Department of Electrical and Computer 
Engineering, Faculty of Electrical Engineering, Szczecin, Poland, 3Department 
of Gastroenterology, Pomeranian Medical University, Szczecin, Poland, 
4Department of Patomorphology, Medical University of Silesia, Katowice, 
Poland and 5Department of Gastroenterology and Hepatology, Medical 
University of Silesia, Katowice, Poland
References
1. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli 
C, Fatta E, Bignamini D, Marchesini G, Fargion S: Risk of severe level 
disease in nonalcoholic fatty liver disease with normal 
aminotransferase levels: a role for insulin resistance and diabetes.  
Hepatology 2008, 48:792-798.
2. Tarantino G, Saldalamacchia G, Conca P, Arena A: Non-alcoholic fatty 
liver disease: further expression of the metabolic syndrome.  J 
Gastroenterol Hepatol 2007, 22:293-303.
3. Tarher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day Ch, 
Arcaro G: Prevalence of nonalcoholic fatty liver disease and its 
association with cardiovascular disease among type 2 diabetic 
patients.  Diabetes Care 2007, 30:1212-1218.
4. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwandet-Tetri BA: 
Development and validation of a simple NAFLD clinical scoring system 
for identifying patients without advanced disease.  Gut 2008, 
57:1441-1447.
5. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, 
Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, 
Kench J, Therneau TB, Day CP: The NAFLD Fibrosis Score: a noninvasive 
system that identifies liver fibrosis in patients with NAFLD.  Hepatology 
2007, 45:846-854.
6. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, 
Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM: Noninvasive 
markers of fibrosis in nonalcoholic fatty liver disease: validating the 
European Liver Fibrosis Panel and exploring simple markers.  
Hepatology 2008, 47:455-460.
7. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM: Non-invasive 
markers associated with liver fibrosis in non-alcoholic fatty liver 
disease.  Gut 2006, 55:1650-1660.
8. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N: 
Applicability of BARD score to Japanese patients with NAFLD.  Gut 
2009, 58:1566-1567.
9. Shah A, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, NASH Clinical 
Research Network: Comparison of noninvasive markers of fibrosis in 
patients with nonalcoholic fatty liver disease.  Clin Gastroenterol Hepatol 
2009, 7(10):1104-1112.
10. Lee RG: Nonalcoholic steatohepatitis: a study of 49 patients.  Human 
Pathology 1989, 20:594-8.
11. Angulo P, Alba LM, Petrovic LM: Leptin, insulin resistance, and liver 
fibrosis in human nonalcoholic fatty liver disease.  J.Hepatol 2004, 
41:943-9.
12. Chwist A, Hartleb M, Kacperek-Hartleb T, Kajor M, Kukla M, Żwirska-
Korczala K: Insulin resistance may better identify fibrosis in non-
alcoholic fatty liver disease (NAFLD) than serum adipocytokines.  J 
Hepatol 2009, 50:S358.
13. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, 
McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty 
liver disease: a feature of the metabolic syndrome.  Diabetes 2001, 
50:1844-1850.
14. Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland 
T, Birkeland K, Bjøro K: Abnormal glucose tolerance is a predictor of 
steatohepatitis and fibrosis in patients with non-alcoholic fatty liver 
disease.  Scand J Gastroenterol 2005, 40(12):1469-77.
15. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, 
Pasanisi F, Contaldo F, Scopacasa F, Capone D: Enhanced serum 
concentrations of transforming growth factor-beta1 in simple fatty 
liver: is it really benign?  J Transl Med 2008, 6:72-79.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/10/67/prepub
doi: 10.1186/1471-230X-10-67
Cite this article as: Raszeja-Wyszomirska et al., Validation of the BARD scor-
ing system in Polish patients with nonalcoholic fatty liver disease (NAFLD) 
BMC Gastroenterology 2010, 10:67
Received: 20 April 2010 Accepted: 28 June 2010 
Published: 28 June 2010
This article is available from: http://www.biomedcentral.com/1471-230X/10/67 © 2010 Raszeja-Wyszomirska et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Gastroenterology 2010, 10:67